Killik hails major Glaxo deal with Novartis
Killik has maintained a 'buy' recommendation on GlaxoSmithKline (GSK), saying that the company's major three-part transaction with Swiss pharmaceuticals peer Novartis on Tuesday will accelerate growth, provide cost savings and generate increased returns. The first part of the deal will see GSK and
Read more